retatrutide safety clinical trial retatrutide drug trials A new clinical from Eli Lilly and Company suggests its experimental eli lilly phase 3 trial Retatrutide Availability & Timeline |

At Week 26, the primary HbA1c endpoint was missing for 4.3%, 4.4% and 4.4% of patients randomized to placebo, semaglutide tablets 7 mg and semaglutide tablets 14 mg, respectively

If the question is "what could I use, with my clinician, now," tirzepatide is the answer with evidence behind it

Individuals using GLP-1 therapies may experience different levels of appetite suppression, digestive changes, and metabolic responses, making it difficult to design a one-size-fits-all nutrition solution

Muneeb Ullah, orcid.org/0009-0007-9150-7796

"While your body naturally produces GLP-1, some people may benefit from medications that mimic its effects." That's where injectables like Ozempic come in

There is no clinical data resolving that question